Alkermes regains the rights to Vivitrol from Cephalon along with $120M in revenue
Alkermes has regained the full US rights to alcoholism treatment Vivitrol (naltrexone) from fellow US drugmaker Cephalon, along with $120.0 million of remaining milestone and deferred revenue from the terminated collaboration.
Under the terms of the agreement, Cephalon will pay Alkermes $11.0 million to cover its share of the estimated losses on Vivitrol for the next 12 months and Alkermes will pay Cephalon $16.0 million to purchase manufacturing equipment for the product. Alkermes says it will recognize the remaining milestones and deferred revenue of around $120.0 million related to its previous agreements with Cephalon as net collaborative profit in the third quarter of fiscal 2009. Further terms of the agreement were not disclosed.
Cephalon says it "cannot give Vivitrol the focus it deserves"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze